Whitehawk Therapeutics (NASDAQ:WHWK) Issues Earnings Results

Whitehawk Therapeutics (NASDAQ:WHWK) issued its earnings results on Thursday. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.10, Zacks reports.

Whitehawk Therapeutics Stock Performance

NASDAQ:WHWK opened at $4.76 on Friday. The firm has a market cap of $235.38 million, a P/E ratio of -4.25 and a beta of 0.76. The firm’s fifty day moving average is $4.11 and its 200-day moving average is $3.78. Whitehawk Therapeutics has a 52 week low of $1.57 and a 52 week high of $5.49.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on WHWK. Leerink Partners assumed coverage on Whitehawk Therapeutics in a research note on Monday, July 13th. They issued an “outperform” rating and a $9.00 price target for the company. B. Riley Financial started coverage on Whitehawk Therapeutics in a report on Thursday, June 25th. They issued a “buy” rating and a $10.00 target price for the company. Citizens Jmp started coverage on Whitehawk Therapeutics in a research report on Thursday, April 16th. They issued a “market outperform” rating and a $8.00 target price for the company. Wall Street Zen raised Whitehawk Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Citigroup started coverage on Whitehawk Therapeutics in a research note on Thursday, April 16th. They issued an “outperform” rating for the company. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $8.20.

Institutional Trading of Whitehawk Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quadrature Capital Ltd bought a new position in shares of Whitehawk Therapeutics in the 4th quarter worth $28,000. Geode Capital Management LLC grew its position in Whitehawk Therapeutics by 11.4% in the 4th quarter. Geode Capital Management LLC now owns 425,440 shares of the company’s stock valued at $1,030,000 after purchasing an additional 43,686 shares during the period. Dimensional Fund Advisors LP bought a new stake in Whitehawk Therapeutics during the 3rd quarter valued at $84,000. Jane Street Group LLC increased its stake in Whitehawk Therapeutics by 177.3% during the 4th quarter. Jane Street Group LLC now owns 69,931 shares of the company’s stock valued at $169,000 after purchasing an additional 44,716 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in Whitehawk Therapeutics during the fourth quarter worth $164,000. 52.08% of the stock is owned by institutional investors.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.